HUM

Humana Inc. NYQ · HUM

$397.60 -6.74 (-1.67%)

Neutral · +0.56σ

+ Compare Open in Sniper

Mkt cap $47.7B

P/E 42.4

Day $394.86 – $404.61

52wk $163.11 – $428.88

Avg vol 1.6M

Beta 0.72

Div yld 0.88%

Next earnings —

Quick read

At a glance

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell.

HUM last traded at $397.60, down 1.7% on the day; that's in the upper part of its 52-week range ($163.11–$428.88). Right now it's trading close to its recent average, with no strong stretch in either direction.

Earnings reports are the biggest scheduled catalysts to keep an eye on, and day to day, watch whether it holds above or slips below its recent average.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is stretched slightly above its normal range — a light stretch — early days, worth watching.

Long —

Setup score 16 / 100

Price is sitting close to its normal range — no real dip to buy yet.

· Aligned with breakout up (strong tailwind)

Technical read: above KC1 lower, +0.51 ATR from EMA21 · no notable pattern

What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.

Score split: chart signals 16 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 16 pts

Cycle position 6

Market fit 10

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short —

Setup score 20 / 100

Price is stretched slightly above its normal range — a light stretch — early days, worth watching.

· KC1 upper stretch — light pop
· RSI hook from overbought (58)
· Counter-trend short in breakout up

Technical read: KC1 upper, +0.51 ATR from EMA21 · no notable pattern

What it means: Price is stretched slightly above its normal range — a light stretch — early days, worth watching. The trigger bar shows no standout candle signal yet.

Score split: chart signals 20 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.

How this grade was earned

total 20 pts

Cycle position 14

Momentum 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →

21 EMA +1 ATR +2 ATR −2 ATR

—

O — H — L — C —

— —

Valuation & accounting

Valuation desk →

Our cash-flow model pegs fair value near $668.95 (fair range $168–$3240); today's price leaves a +39% cushion below that estimate. The model's verdict is “Deep value” and accounting quality screens as Adequate. Model estimates only — do your own due diligence.

Deep value +39% margin of safety Accounting: Adequate

Intrinsic (DCF)

$668.95

Fair-value range

$168.48 – $3239.94

Margin of safety

+39%

Accounting quality Adequate

✓ More cash than debt
✓ Positive retained earnings

⚠ Receivables growing faster than revenue

Price implies ~14% growth (vs trailing rev yoy). Model estimate — do your own due diligence.

Key statistics

All statistics →

HUM is a $47.7 billion company, priced at 42× last year's earnings, and the stock is trading near the top of its 52-week range.

Market cap $47.7B

P/E ttm 42.4

Beta 0.72

52w range $163.11 – $428.88

Avg volume 1.6M

Dividend yield 0.88%

Sector Healthcare

Next earnings —

52-week range · today's price

$163.11$428.88

More on HUM

Options idea

See more →

CALL $410 2026-08-21

$25.88

PUT $410 2026-08-21

$33.28

Earnings

See more →

Last reported: 2026-04-29
EPS (act / est): 10.31 / 10.20
Surprise: +1.1%
Next report: 2026-07-29

About

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products…